Market Overview:
The global orphan diseases market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of orphan diseases, rising awareness about orphan drugs, and technological advancements in the field of orphan drugs. The global orphan diseases market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into ocology, hematology, neurology, endocrinology, cardiovascular disease (CVD), respiratory disease (RD), immunotherapy and others. The ocology segment is expected to grow at a CAGR of 11% from 2018 to 2030 due to increasing incidence rates for rare cancers such as ovarian cancer and pancreatic cancer. The hematology segment accounted for the second-largest share in 2017 owing to an increase in demand for therapies such as erythropoiesis stimulating agents (ESAs) and granulocyte colony-stimulating factors (G-CSFs). On the basis of application, hospital pharmacy accounted for majority share in 2017 owing higher adoption rates for expensive injectable therapies used across various therapeutic areas including oncology & hemato-oncology; autoimmune disorders; genetic disorders; central nervous system disorders; gastrointestinal disorders; metabolic disorders etc.
Product Definition:
The Orphan Drug Act (ODA) of 1983 defines an orphan drug as a pharmaceutical agent intended to treat a rare disease or condition, which is generally considered to affect fewer than 200,000 Americans. The ODA provides incentives for the development and marketing of these drugs, including tax breaks and seven years of market exclusivity following approval by the U.S. Food and Drug Administration (FDA).
Orphan diseases are important because they can often be very difficult to diagnose and/or treat, leaving patients with few options. In addition, many orphan diseases are associated with significant disability or even death.
Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2016 VS 2021 VS 2027:
Global orphan diseases are rare disorders that occur in one out of every 100 people. They are also known as rare diseases. The number of orphan drugs is increasing rapidly and the market for these drugs is growing at a rapid pace, which has led to an increase in demand for better diagnosis tools to identify them.
Ocology:
Ocology is the branch of medicine that deals with diseases of the eye, ear, nose, and throat.
Application Insights:
The others segment dominated the global orphan diseases market in 2017, accounting for over 40% of the overall revenue share. This is owing to a large number of rare diseases that affect fewer patients, rendering unmet medical needs and high potential for future growth. The hospital pharmacy segment accounted for a significant revenue share in North America and Europe as many pharmaceutical companies have their regional offices or headquarters located within these regions to serve smaller markets more efficiently.
The retail pharmacy sector is also expected to witness lucrative growth over the forecast period due to increasing awareness among people regarding availability of treatments at affordable costs rather than depending upon government healthcare facilities or private hospitals which are often far away from their residences thus making them dependent on expensive transport fares leading to higher spending capacity among individuals with similar income levels thus resulting in increased demand for medicines across all age groups especially during emergencies when last-minute treatment options are available through this channel only.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2018. The presence of a large number of orphan drug manufacturers and favorable government initiatives are some factors attributing to its largest market share. For instance, FDA has approved more than 300 orphan drug products since 2001 which have a potential to treat about 80 rare diseases. In addition, increasing R&D activities by pharmaceutical companies is also expected to contribute towards the growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure and improving economic conditions in emerging countries such as China & India & South Korea etcetera (EMSE). Moreover, growing awareness regarding various treatment options for orphan diseases coupled with an increase in disposable income will drive this regional market further during the forecast years from 2019-2030 to 2030-29 showing significant CAGR exceeding 13% per annum rate during estimated time span.
Growth Factors:
- Increasing prevalence of orphan diseases: The incidence of orphan diseases is increasing due to various factors such as environmental changes, genetic mutations, and others. This is expected to drive the growth of the orphan drugs market in the coming years.
- Development of novel therapies: The development of novel therapies for treating rare diseases is a major growth driver for the orphan drugs market. There are numerous pipeline products in different stages of development that are expected to be launched in the next few years, which will boost the market growth.
- Rising awareness about rare diseases: There is a growing awareness among people about rare diseases and their symptoms owing to increased public-private initiatives and campaigns by various organizations worldwide. This is likely to create demand for better diagnosis and treatment options for these disorders, thereby propelling market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Orphan Diseases Market Research Report
By Type
Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2016 VS 2021 VS 2027, Ocology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, Others
By Application
Hospital Pharmacy, Retail Pharmacy, Others
By Companies
Bristol-Myers Squibb, Novartis, Celgene, Roche, Pfizer, Alexion, Sanofi, Vertex Pharmaceuticals, GlaxoSmithKline, Merck, Abbvie
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
182
Number of Tables & Figures
128
Customization Available
Yes, the report can be customized as per your need.
Global Orphan Diseases Market Report Segments:
The global Orphan Diseases market is segmented on the basis of:
Types
Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2016 VS 2021 VS 2027, Ocology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Novartis
- Celgene
- Roche
- Pfizer
- Alexion
- Sanofi
- Vertex Pharmaceuticals
- GlaxoSmithKline
- Merck
- Abbvie
Highlights of The Orphan Diseases Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2016 VS 2021 VS 2027
- Ocology
- Hematology
- Neurology
- Endocrinology
- Cardiovascular
- Respiratory
- Immunotherapy
- Others
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Orphan Diseases Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Orphan diseases are diseases that affect only a small number of people.
Some of the major companies in the orphan diseases market are Bristol-Myers Squibb, Novartis, Celgene, Roche, Pfizer, Alexion, Sanofi, Vertex Pharmaceuticals, GlaxoSmithKline, Merck, Abbvie.
The orphan diseases market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Orphan Diseases Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Orphan Diseases Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Orphan Diseases Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Orphan Diseases Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Orphan Diseases Market Size & Forecast, 2018-2028
4.5.1 Orphan Diseases Market Size and Y-o-Y Growth
4.5.2 Orphan Diseases Market Absolute $ Opportunity
Chapter 5 Global Orphan Diseases Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Orphan Diseases Market Size Forecast by Type
5.2.1 Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2016 VS 2021 VS 2027
5.2.2 Ocology
5.2.3 Hematology
5.2.4 Neurology
5.2.5 Endocrinology
5.2.6 Cardiovascular
5.2.7 Respiratory
5.2.8 Immunotherapy
5.2.9 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Orphan Diseases Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Orphan Diseases Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Orphan Diseases Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Orphan Diseases Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Orphan Diseases Analysis and Forecast
9.1 Introduction
9.2 North America Orphan Diseases Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Orphan Diseases Market Size Forecast by Type
9.6.1 Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2016 VS 2021 VS 2027
9.6.2 Ocology
9.6.3 Hematology
9.6.4 Neurology
9.6.5 Endocrinology
9.6.6 Cardiovascular
9.6.7 Respiratory
9.6.8 Immunotherapy
9.6.9 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Orphan Diseases Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Retail Pharmacy
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Orphan Diseases Analysis and Forecast
10.1 Introduction
10.2 Europe Orphan Diseases Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Orphan Diseases Market Size Forecast by Type
10.6.1 Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2016 VS 2021 VS 2027
10.6.2 Ocology
10.6.3 Hematology
10.6.4 Neurology
10.6.5 Endocrinology
10.6.6 Cardiovascular
10.6.7 Respiratory
10.6.8 Immunotherapy
10.6.9 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Orphan Diseases Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Retail Pharmacy
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Orphan Diseases Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Orphan Diseases Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Orphan Diseases Market Size Forecast by Type
11.6.1 Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2016 VS 2021 VS 2027
11.6.2 Ocology
11.6.3 Hematology
11.6.4 Neurology
11.6.5 Endocrinology
11.6.6 Cardiovascular
11.6.7 Respiratory
11.6.8 Immunotherapy
11.6.9 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Orphan Diseases Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Retail Pharmacy
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Orphan Diseases Analysis and Forecast
12.1 Introduction
12.2 Latin America Orphan Diseases Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Orphan Diseases Market Size Forecast by Type
12.6.1 Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2016 VS 2021 VS 2027
12.6.2 Ocology
12.6.3 Hematology
12.6.4 Neurology
12.6.5 Endocrinology
12.6.6 Cardiovascular
12.6.7 Respiratory
12.6.8 Immunotherapy
12.6.9 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Orphan Diseases Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Retail Pharmacy
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Orphan Diseases Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Orphan Diseases Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Orphan Diseases Market Size Forecast by Type
13.6.1 Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2016 VS 2021 VS 2027
13.6.2 Ocology
13.6.3 Hematology
13.6.4 Neurology
13.6.5 Endocrinology
13.6.6 Cardiovascular
13.6.7 Respiratory
13.6.8 Immunotherapy
13.6.9 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Orphan Diseases Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Retail Pharmacy
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Orphan Diseases Market: Competitive Dashboard
14.2 Global Orphan Diseases Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb
14.3.2 Novartis
14.3.3 Celgene
14.3.4 Roche
14.3.5 Pfizer
14.3.6 Alexion
14.3.7 Sanofi
14.3.8 Vertex Pharmaceuticals
14.3.9 GlaxoSmithKline
14.3.10 Merck
14.3.11 Abbvie
